Bone resorption disease

Summary

Bone resorption disease (MONDO:0000837) is a disease. A subtype of bone remodeling disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	bone resorption disease
Mondo ID	MONDO:0000837
MeSH	D001862
DOID	DOID:0080011
UMLS	C0005974
MedGen	14188
Is cancer (heuristic)	no

Disease family

This is a subtype of bone remodeling disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › skeletal system disorder › bone disorder › bone remodeling disease › bone resorption disease

Related subtypes (5): fibrous dysplasia, osteomalacia, hyperostosis, osteosclerosis, rickets

Subtypes (3): osteoporosis, osteitis fibrosa, lytic metastatic bone lesion

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

2 approved. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Calcitonin Salmon	Approved (phase 4)
Denosumab	Approved (phase 4)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Alendronic Acid.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.